The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort

Babayigit et al., Frontiers in Medicine, doi:10.3389/fmed.2022.894126

Babayigit et al., The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide.., Frontiers in Medicine, doi:10.3389/fmed.2022.894126

Aug 2022 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 1,472 hospitalized patients in Turkey, showing a higher risk of ICU admission and ventilation with HCQ, without statistical significance.

Important missing comments or errors? Let us know.

This study includes HCQ and favipiravir.

risk of mechanical ventilation, 112.4% higher, RR 2.12, p = 0.21, treatment 63 of 1,378 (4.6%), control 6 of 94 (6.4%), adjusted per study, odds ratio converted to relative risk, multivariable.

risk of ICU admission, 52.8% higher, RR 1.53, p = 0.33, treatment 107 of 1,363 (7.9%), control 9 of 93 (9.7%), adjusted per study, odds ratio converted to relative risk, multivariable.

hospitalization time, 16.7% higher, relative time 1.17, p = 0.05, treatment 852, control 63.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Babayigit et al., 31 Aug 2022, retrospective, Turkey, peer-reviewed, mean age 51.9, 68 authors, study period 11 March, 2020 - 18 July, 2020.

Contact: habayram@ku.edu.tr.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort

Cenk Babayigit, Nurdan Kokturk, Seval Kul, Pelin Duru Cetinkaya, Sibel Atis Nayci, Serap Argun Baris, Oguz Karcioglu, Pinar Aysert, Ilim Irmak, Aycan Akbas Yuksel, Yonca Sekibag, Oya Baydar Toprak, Emel Azak, Sait Mulamahmutoglu, Caglar Cuhadaroglu, Aslihan Demirel, Bugra Kerget, Burcu Baran Ketencioglu, Hasan Selcuk Ozger, Gulcihan Ozkan, Zeynep Ture, Begum Ergan, Vildan Avkan Oguz, Oguz Kilinc, Merve Ercelik, Tansu Ulukavak Ciftci, Ozlem Alici, Esra Nurlu Temel, Ozlem Ataoglu, Asena Aydin, Dilek Cetiner Bahcetepe, Yusuf Taha Gullu, Fusun Fakili, Figen Deveci, Neslihan Kose, Muge Meltem Tor, Gulsah Gunluoglu, Sedat Altin, Teyfik Turgut, Tibel Tuna, Onder Ozturk, Oner Dikensoy, Pinar Yildiz Gulhan, Ilknur Basyigit, Hasim Boyaci, Ipek Kivilcim Oguzulgen, Sermin Borekci, Bilun Gemicioglu, Firat Bayraktar, Osman Elbek, Ismail Hanta, Hacer Kuzu Okur, Gulseren Sagcan, Oguz Uzun, Metin Akgun, Goksel Altinisik, Berna Dursun, Ebru Cakir Edis, Erkmen Gulhan, Fusun Oner Eyuboglu, Okkes Gultekin, Yavuz Havlucu, Metin Ozkan, Aysin Sakar Coskun, Abdullah Sayiner, A Fuat Kalyoncu, Oya Itil, Hasan Bayram

Frontiers in Medicine, doi:10.3389/fmed.2022.894126

Furthermore, favipiravir was associated with increased risks of ICU admission (OR [95% CI]: 3.02 [1.70-5.35]; p = 0.001) and invasive mechanical ventilation requirement (OR [95% CI]: 2.94 [1.28-6.75]; p = 0.011). Conclusion: Our findings demonstrated that antiviral drugs including lopinavir, ritonavir, and favipiravir were associated with negative clinical outcomes such as increased risks for lengthy hospital stay, ICU admission, and invasive mechanical ventilation requirement. Therefore, repurposing such agents without proven clinical evidence might not be the best approach for COVID-19 treatment.

Ethics statement The studies involving human participants were reviewed and approved by Institutional Review Board of Gazi University Faculty of Medicine, Ankara, Turkey (356/22.05.2020). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. Author contributions CB, NKk, HBa, OI, FO, AS, ASC, BD, and AK designed the study. CB, NKk, PC, SAB, OKa, PA, II, AAk, YS, OB, EA, SM, CC, AD, BK, BB, HO, GO, ZT, BE, VA, OKi, ME, TU, OAl, EN, OAt, AAy, DC, YG, FF, FD, NKs, MT, GG, SA, TeT, TiT, OO, OD, PY, IB, HBo, IO, SB, BG, FB, OE, IH, HK, GS, OU, MA, GA, BD, EC, EG, OG, YH, MO, and ASC collected the data. SK and SAN analyzed the data. CB, NKk, SK, and HBa searched the literature and wrote the manuscript. CB, NKk, SK, SAB, PC, and HBa edited and revised manuscript according to journal's instructions. CB, NKk, SK, PC, SAB, and HBa edited and controlled the final version of the manuscript. All authors approved the final version of the manuscript. Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer BH declared a shared affiliation with the authors, II and AK to the handling editor at the time of review. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of..

References

Antoniou, Dilaveris, Manolakou, Galanakos, Magkas et al., QT prolongation and malignant arrhythmia: How serious a problem?, Eur Cardiol, doi:10.15420/ecr.2017:16:1

Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.099

Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19-final report, N Engl J Med, doi:10.1056/NEJMoa2007764

Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N Engl J Med, doi:10.1056/NEJMoa2116044

Catteau, Dauby, Montourcy, Bottieau, Hautekiet et al., Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: A nationwide observational study of 8075 participants, Int J Antimicrob Agents

Chan, Lai, Chu, Tsui, Tam et al., Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort study, Hong Kong Med J

Chinello, Petrosillo, Pittalis, Biava, Ippolito et al., Cardiac safety of off-label COVID-19 drug therapy: A review and proposed monitoring protocol, Eur Heart J Acute Cardiovasc Care, doi:10.1177/2048872620922784

Choy, Wong, Kaewpreedee, Sia, Chen et al., None

Covid, 19 Risk and Treatments (Corist) Collaboration. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study, Eur J Intern Med

Croxtall, Perry, Lopinavir/Ritonavir: A review of its use in the management of HIV-1 infection, Drugs, doi:10.2165/11204950-000000000-00000

Doi, Hibino, Hase, Yamamoto, Kasamatsu et al., A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19, Antimicrob Agents Chemother, doi:10.1128/AAC.01897-20

Fiolet, Guihur, Rebeaud, Mulot, Peiffer-Smadja et al., Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): A randomised clinical trial, Clin Microbiol Infect, doi:10.1016/S0140-6736(20)31862-6

Food, Coronavirus (COVID-19) update: FDA Authorizes additional oral antiviral for treatment of COVID-19 in certain adults

Gao, Tian, Yang, Wei, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.1097/CM9.0000000000000819

Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2012410

Ghafar, Efficacy of favipiravir in COVID-19 treatment: A multi-center randomized study, Arch Virol, doi:10.1007/s00705-021-04956-9

Guner, Hasanoglu, Kayaaslan, Aypak, Akinci et al., Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir, J Infect Public Health, doi:10.14744/nci.2021.60420

Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): Interim results of a phase II/III multicenter randomized clinical trial, Clin Infect Dis, doi:10.1093/cid/ciaa1176

Joshi, Parkar, Ansari, Vora, Talwar et al., Role of favipiravir in the treatment of COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.10.069

Karim, Repurposed antiviral drugs for covid-19 -interim WHO solidarity trial results, N Engl J Med, doi:10.1056/NEJMx200021

Kokturk, Babayigit, Kul, Cetinkaya, Nayci et al., The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients, Respir Med, doi:10.1016/j.rmed.2021.106433

Manabe, Kambayashi, Akatsu, Kudo, Ghanei et al., Favipiravir for the treatment of patients with COVID-19: A systematic review and meta-analysis, Br MC Infect Dis, doi:10.1186/s12879-021-06164-x

Mitjà, Corbacho-Monné, Ubals, Tebé, Peñafiel et al., Hydroxychloroquine for early treatment of adults with mild Covid-19: A randomized-controlled trial, Clin Infect Dis, doi:10.1093/cid/ciaa1009

Pan, Peto, Henao-Restrepo, Preziosi, Sathiyamoorthy, None

Pilkington, Pepperrell, Hill, A review of the safety of favipiravira potential treatment in the COVID-19 pandemic?, J Virus Erad, doi:10.1016/S2055-6640(20)30016-9

Ranieri, Rubenfeld, Thompson, Ferguson, classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against rheumatism/American College of rheumatology/paediatric rheumatology international trials organisation collaborative initiative, Ann Rheum Dis, doi:10.1378/chest.101.6.1644

Remdesivir, Cao, Wang, Wen, Liu et al., A trial of lopinavirritonavir in adults hospitalized with severe covid-19, Antiviral Res, doi:10.1056/NEJMc2008043

Rice, Janj, Kokturk, Kul, Cetinkaya et al., In defence of evidence-based medicine for the treatment of COVID-19 acute respiratory distress syndrome, doi:10.1513/AnnalsATS.202004-325IP

Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with inhospital mortality in patients with COVID-19 in New York state, JAMA, doi:10.1001/jama.2020.8630

Saadat, Safety and efficacy of favipiravir in moderate to severe SARS-CoV-2 pneumonia, Int Immunopharmacol, doi:10.1016/j.intimp.2021.107522

Soltane, Elmaaty, Tantawy, Antar, Yahya, Coronavirus disease (COVID-19) control between drug repurpising and vaccination: A comprehensive overview, Vaccines, doi:10.3390/vaccines9111317

Spinner, Gottlieb, Criner, López, Cattelan et al., FDA approves first treatment for COVID-19

Sun, Deng, Chen, Huang, Huang et al., Incidence of adverse drug reactions in COVID-19 patients in China: An active monitoring study by hospital pharmacovigilance system, Clin Pharmacol Ther, doi:10.1002/cpt.1866

Viladomiu, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A Randomized clinical trial, Ann Intern Med, doi:10.7326/M20-5752

Wang, Cao, Zhang, Xinglou, Jia et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0

Wu, Chen, Cai, Xia, Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, doi:10.1001/jamainternmed.2020.0994

Yousefi, Valizadeh, Ghaffari, Vahedi, Karbalaei et al., A global treatment for coronaviruses including COVID-19, J Cell Physiol, doi:10.1002/jcp.29785

Özlüşen, Kozan, Akcan, Kalender, Yaprak et al., Effectiveness of favipiravir in COVID-19: A live systematic review, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-021-04307-1

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit